Drug Target Identification
The Centre will identify and validate tumour cell proteins and pathways (targets) critical for maintaining the malignant phenotype that may serve as therapeutic targets. We envisage extensive iterative research, leveraging insights into tumour biology generated in Stage 1
activities and collaborative ICBTB input. Activities will include in vitro and in vivo target validation including identification of the targets of active agents discovered in Stage 3 phenotypic screens.
The groups involved in this stage of the pipeline are: